Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation-Reference-Cited by-同舟云学术

Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation

Published:2018-02 Issue:2 Volume:54 Page:221-228
ISSN:0749-3797
Container-title:American Journal of Preventive Medicine
language:en
Short-container-title:American Journal of Preventive Medicine

Author:

Hull Leland E.,Haas Jennifer S.,Simon Steven R.

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Epidemiology

Reference48 articles.

1. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer;Couch;N Engl J Med,1997

2. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2. Dis Markers;Frank,1999

3. The role of risk-reducing surgery in hereditary breast and ovarian cancer;Hartmann;N Engl J Med,2016

4. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation;Meijers-Heijboer;N Engl J Med,2001

5. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group;Rebbeck;J Clin Oncol,2004

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uptake of Cancer Genetic Services for Chatbot vs Standard-of-Care Delivery Models;JAMA Network Open;2024-09-09

2. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing;British Journal of Cancer;2024-08-30

3. Systematic evidence review and meta-analysis of outcomes associated with cancer genetic counseling;Genetics in Medicine;2024-01

4. Combining rare and common genetic variants improves population risk stratification for breast cancer;Genetics in Medicine Open;2024

5. Comprehensive assessment of hereditary cancer risk using artificial intelligence (AI) chatbot for women undergoing gynecological cancer screening;Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening);2024